{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:34:19Z","timestamp":1787009659521,"version":"build-2736575974"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novartis Korea Ltd"},{"name":"Novartis Korea"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe the incidence rates of inflammatory bowel disease (IBD) and tuberculosis (TB) in Korean patients with ankylosing spondylitis receiving biologics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from a Korean claims database between 2010 and 2021 was used to calculate crude incidence rates of TB and IBD using number of events and total patient-years (PYs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 43\u2009643 and 43\u2009396 patients were included in TB and IBD cohorts, respectively. Exposure-adjusted incidence rates (EAIRs) of TB for non-exposure, TNF inhibitors (TNFis), and IL-17 inhibitors (IL-17is) were 0.14, 0.25 and 0.12 and of IBD were 0.18, 0.19 and 0.44 per 100 PYs, respectively. Incidence rates during biologic DMARD (bDMARD) non-exposure, adalimumab, etanercept, golimumab, infliximab, secukinumab and ixekizumab exposures for TB were 13.96, 27.79, 14.28, 21.19, 33.62, 12.74 and 0.00 and for IBD were 18.29, 19.98, 22.41, 18.85, 15.73, 44.99 and 0.00 per 10\u2009000 PYs, respectively. Compared with bDMARD non-exposure, adalimumab, golimumab and infliximab exposures were associated with a significantly higher risk of TB. Etanercept and secukinumab exposure showed no significant increase in risk of TB. Compared with bDMARD non-exposure, exposure to biologics did not show a significant difference in risk of IBD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>EAIRs of TB and IBD with use of IL-17is in patients with AS were within anticipated low range. IL-17is had numerically lower incidence of TB, and numerically higher incidence of IBD compared with TNFis. Notably, secukinumab showed no increased risk of TB compared with bDMARD non-exposure. Neither TNFis nor IL-17is showed increased risk of IBD compared with bDMARD non-exposure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf038","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T23:16:52Z","timestamp":1737501412000},"page":"3518-3525","source":"Crossref","is-referenced-by-count":1,"title":["Incidence rates of tuberculosis and inflammatory bowel disease in patients with ankylosing spondylitis treated with biologics in Korea"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7962-3697","authenticated-orcid":false,"given":"Oh Chan","family":"Kwon","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine , Seoul, South","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6328-6948","authenticated-orcid":false,"given":"Hye Sun","family":"Lee","sequence":"additional","affiliation":[{"name":"Biostatistics Collaboration Unit, Yonsei University College of Medicine , Seoul, South","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juyeon","family":"Yang","sequence":"additional","affiliation":[{"name":"Biostatistics Collaboration Unit, Yonsei University College of Medicine , Seoul, South","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Paul","sequence":"additional","affiliation":[{"name":"Novartis Korea Ltd , Seoul, South","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyerim","family":"Jin","sequence":"additional","affiliation":[{"name":"Novartis Korea Ltd , Seoul, South","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youkyung","family":"Lee","sequence":"additional","affiliation":[{"name":"Novartis Korea Ltd , Seoul, South","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1189-7637","authenticated-orcid":false,"given":"Min-Chan","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine , Seoul, South","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"2025052703533096600_keaf038-B1","first-page":"e52559","article-title":"Diagnosis and treatment of ankylosing spondylitis","volume":"16","author":"Agrawal","year":"2024","journal-title":"Cureus"},{"key":"2025052703533096600_keaf038-B2","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","article-title":"Ankylosing spondylitis","volume":"369","author":"Braun","year":"2007","journal-title":"Lancet"},{"key":"2025052703533096600_keaf038-B3","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40744-019-0160-8","article-title":"Insight into the quality of life of patients with ankylosing spondylitis: real-world data from a US-based life impact survey","volume":"6","author":"Rosenbaum","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2025052703533096600_keaf038-B4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4078\/jrd.2024.0029","article-title":"The effectiveness of tumor necrosis factor-\u03b1 blocker therapy in patients with axial spondyloarthritis who failed conventional treatment: a comparative study focused on improvement in ASAS Health Index","volume":"31","author":"Choi","year":"2024","journal-title":"J Rheum Dis"},{"key":"2025052703533096600_keaf038-B5","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s10067-018-4086-2","article-title":"Evaluation of the comorbidity burden in patients with ankylosing spondylitis using a large US administrative claims data set","volume":"37","author":"Walsh","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2025052703533096600_keaf038-B6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025052703533096600_keaf038-B7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4078\/jrd.2023.0025","article-title":"Korean treatment recommendations for patients with axial spondyloarthritis","volume":"30","author":"Seo","year":"2023","journal-title":"J Rheum Dis"},{"key":"2025052703533096600_keaf038-B8","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3349\/ymj.2023.0151","article-title":"Drug retention rate and factors associated with discontinuation of interleukin-17 inhibitors in patients with axial spondyloarthritis","volume":"64","author":"Kwon","year":"2023","journal-title":"Yonsei Med J"},{"key":"2025052703533096600_keaf038-B9","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s40264-014-0224-1","article-title":"Safety profile of biological medicines as compared with non-biologicals: an analysis of the Italian spontaneous reporting system database","volume":"37","author":"Cutroneo","year":"2014","journal-title":"Drug Saf"},{"key":"2025052703533096600_keaf038-B10","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.3390\/jcm9041227","article-title":"Safety profile of biologics used in rheumatology: an Italian prospective pharmacovigilance study","volume":"9","author":"Barbieri","year":"2020","journal-title":"J Clin Med"},{"key":"2025052703533096600_keaf038-B11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/ard-2022-223357","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Sepriano","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025052703533096600_keaf038-B12","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/ard-2022-223298","article-title":"Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis","volume":"82","author":"Webers","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025052703533096600_keaf038-B13","doi-asserted-by":"crossref","first-page":"1759720x20930116","DOI":"10.1177\/1759720X20930116","article-title":"Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors","volume":"12","author":"Evangelatos","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2025052703533096600_keaf038-B14","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1016\/S2665-9913(19)30012-8","article-title":"Tuberculosis in inflammatory arthritis: are biological therapies the only culprits?","volume":"1","author":"Fragoulis","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"2025052703533096600_keaf038-B15","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1183\/09031936.00028510","article-title":"The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement","volume":"36","author":"Solovic","year":"2010","journal-title":"Eur Respir J"},{"key":"2025052703533096600_keaf038-B16","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1038\/s41423-021-00694-9","article-title":"Reactivation of latent tuberculosis with TNF inhibitors: critical role of the beta 2 chain of the IL-12 receptor","volume":"18","author":"Robert","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"2025052703533096600_keaf038-B17","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/1756-185X.14076","article-title":"Interleukin-17 inhibitor, is it safer than tumor necrosis factor inhibitor?","volume":"24","author":"Huang","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"2025052703533096600_keaf038-B18","author":"Global tuberculosis report [Internet]","year":"2023"},{"key":"2025052703533096600_keaf038-B19","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s10067-013-2387-z","article-title":"Comparison of tuberculosis incidence in ankylosing spondylitis and rheumatoid arthritis during tumor necrosis factor inhibitor treatment in an intermediate burden area","volume":"33","author":"Kim","year":"2014","journal-title":"Clin Rheumatol"},{"key":"2025052703533096600_keaf038-B20","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/annrheumdis-2013-203582","article-title":"Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis","volume":"74","author":"Stolwijk","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025052703533096600_keaf038-B21","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1136\/annrheumdis-2014-205253","article-title":"The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study","volume":"74","author":"Stolwijk","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025052703533096600_keaf038-B22","doi-asserted-by":"crossref","first-page":"578732","DOI":"10.3389\/fimmu.2020.578732","article-title":"Increased Risk of Inflammatory Bowel Disease Among Patients With Ankylosing Spondylitis: a 13-Year Population-Based Cohort Study","volume":"11","author":"Wang","year":"2020","journal-title":"Front Immunol"},{"key":"2025052703533096600_keaf038-B23","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3346\/jkms.2017.32.5.718","article-title":"Towards actualizing the value potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data","volume":"32","author":"Kim","year":"2017","journal-title":"J Korean Med Sci"},{"key":"2025052703533096600_keaf038-B24","author":"World Health Organization","year":"2019"},{"key":"2025052703533096600_keaf038-B25","author":"World Health Organization","year":"2019"},{"key":"2025052703533096600_keaf038-B26","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1161\/ATVBAHA.117.309803","article-title":"Variability in total cholesterol is associated with the risk of end-stage renal disease: a nationwide population-based study","volume":"37","author":"Kim","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2025052703533096600_keaf038-B27","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1210\/jc.2017-00643","article-title":"Cardiovascular diseases and life expectancy in adults with type 2 diabetes: a Korean national sample cohort study","volume":"102","author":"Kang","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2025052703533096600_keaf038-B28","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/1756-185X.12530","article-title":"Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden","volume":"18","author":"Jung","year":"2015","journal-title":"Int J Rheum Dis"},{"key":"2025052703533096600_keaf038-B29","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1080\/14397595.2021.1878985","article-title":"The risk factors and incidence of major infectious diseases in patients with ankylosing spondylitis receiving tumor necrosis factor inhibitors","volume":"31","author":"Koo","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2025052703533096600_keaf038-B30","doi-asserted-by":"crossref","first-page":"e0224963","DOI":"10.1371\/journal.pone.0224963","article-title":"A population-based study of tuberculosis incidence among rheumatic disease patients under anti-TNF treatment","volume":"14","author":"Sartori","year":"2019","journal-title":"PLoS One"},{"key":"2025052703533096600_keaf038-B31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jamadermatol.2020.3257","article-title":"Association of secukinumab treatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis","volume":"157","author":"Elewski","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2025052703533096600_keaf038-B32","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s13555-024-01122-2","article-title":"Safety of Secukinumab from 1 Million Patient-Years of Exposure: experience from Post-Marketing Setting and Clinical Trials","volume":"14","author":"Sun","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025052703533096600_keaf038-B33","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.autrev.2015.01.011","article-title":"Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice","volume":"14","author":"Cantini","year":"2015","journal-title":"Autoimmun Rev"},{"key":"2025052703533096600_keaf038-B34","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1172\/JCI39143","article-title":"Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed","volume":"119","author":"Miller","year":"2009","journal-title":"J Clin Invest"},{"key":"2025052703533096600_keaf038-B35","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40257-024-00845-4","article-title":"Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study","volume":"25","author":"Torres","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"2025052703533096600_keaf038-B36","doi-asserted-by":"crossref","first-page":"e012567","DOI":"10.1136\/bmjopen-2016-012567","article-title":"Risk of tuberculosis in patients treated with TNF-\u03b1 antagonists: a systematic review and meta-analysis of randomised controlled trials","volume":"7","author":"Zhang","year":"2017","journal-title":"BMJ Open"},{"key":"2025052703533096600_keaf038-B37","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/art.22669","article-title":"Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents","volume":"57","author":"Braun","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2025052703533096600_keaf038-B38","doi-asserted-by":"crossref","first-page":"17562848211059954","DOI":"10.1177\/17562848211059954","article-title":"Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues","volume":"14","author":"Peyrin-Biroulet","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"2025052703533096600_keaf038-B39","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/acr.24175","article-title":"Low incidence of inflammatory bowel disease adverse events in adalimumab clinical trials across nine different diseases","volume":"73","author":"Elewaut","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025052703533096600_keaf038-B40","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/jphs.12212","article-title":"Evaluation of the comorbidity burden in patients with ankylosing spondylitis treated with tumour necrosis factor inhibitors using a large administrative claims data set","volume":"9","author":"Walsh","year":"2018","journal-title":"J Pharm Health Serv Res"},{"key":"2025052703533096600_keaf038-B41","first-page":"1779","article-title":"Inflammatory bowel disease as a paradoxical reaction to anti-TNF-\u03b1 treatment-a review","volume":"13","author":"Mihai","year":"2023","journal-title":"Life (Basel)"},{"key":"2025052703533096600_keaf038-B42","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/annrheumdis-2018-214273","article-title":"Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials","volume":"78","author":"Schreiber","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025052703533096600_keaf038-B43","doi-asserted-by":"crossref","first-page":"e0233781","DOI":"10.1371\/journal.pone.0233781","article-title":"Risk for development of inflammatory bowel disease under inhibition of interleukin 17: a systematic review and meta-analysis","volume":"15","author":"Burisch","year":"2020","journal-title":"PLoS One"},{"key":"2025052703533096600_keaf038-B44","doi-asserted-by":"crossref","first-page":"1124628","DOI":"10.3389\/fphar.2023.1124628","article-title":"IL-17 inhibitor-associated inflammatory bowel disease: A study based on literature and database analysis","volume":"14","author":"Deng","year":"2023","journal-title":"Front Pharmacol"},{"key":"2025052703533096600_keaf038-B45","doi-asserted-by":"crossref","first-page":"adv00698","DOI":"10.2340\/actadv.v102.563","article-title":"Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data","volume":"102","author":"Gottlieb","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"2025052703533096600_keaf038-B46","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf038\/61621794\/keaf038.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/6\/3518\/61621794\/keaf038.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/6\/3518\/61621794\/keaf038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T03:53:44Z","timestamp":1748318024000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/6\/3518\/7978929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":46,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,1,24]]},"published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf038","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,1,24]]}}}